Vidac Pharma Reports First Patient Dosed in Phase 2b Study of VDA-1102 for High-Risk Actinic Keratosis
Vidac Pharma reports first patient dosed in Phase 2b study of VDA-1102 for high-risk Actinic Keratosis at Centroderm, Germany. Vidac Pharma Holdings PLC (Xetr:T9G, ISIN: GB00BM9XQ619, WKN: A3DTUQ) LONDON, UNITED KINGDOM, February 23, 2026 /EINPresswire. …